Let’s face it, pot is pungent and no matter how you slice it, once you light it in public, everybody within a twenty foot radius knows what you’re up to and like torching a fat Cuban cigar at a bus stop, hardly anyone is appreciative of your activity.
Therefore, vaping has become the option of choice for all the cool kids who want to toke without the smoke and C21 Investments (CXXI.C) just launched their leading-edge Phantom Vape Pen to meet this growing demand.
Although forms of vaping have been around since the fifth century B.C. when Herodotus a.k.a. ‘the father of history’, wrote about Scythians tossing hemp-seed on red-hot stones, it wasn’t until 2006 that Chinese pharmacist Hon Lik made and sold the first e-cigarette.
The technology behind modern vaping pens is still new and has its own challenges regarding consistency of dose, shelf stability and liquid viscosity.
Phantom Farms, a Clean Green Certified cannabis grower in Oregon, designed the Phantom Vape Pen to address many of these issues.
Using advanced C CELL technology with Phantom Farms’ proprietary terpene-heavy CO2 extraction, the company has created a device that keeps the natural terpene flavours while providing consistent potency, putting the Phantom Vape Pen at the technological forefront of cannabis vaping in a rapidly growing global vaping market.
“Vaping is the main driver of concentrate sales, which are projected to reach $8.4 billion in USA sales by 2022,” said Sky Pinnick, Chief Marketing Officer, C21 Investments. “Our strategy for the Phantom Vape Pen was to provide an affordable, superior product at a highly competitive price point helping to bridge the gap for flower traditionalists to high quality concentrates.”
C21 Investments is marketing the Phantom Vape Pen as part of a broader strategy to supply its wholesale partners a spectrum of vaping products at various competitive price points across C21’s concentrate segment which includes Dab Society, Hood Oil and Phantom Farms.
The Phantom Vape Pen is currently on shelves in dispensaries across the state of Oregon and in due time, C21 expects that its industry-leading product will also be in dispensaries in Nevada.
C21 recently released unaudited financials for the two months ending March 31, 2019, reporting USD$5.1 million in revenue and gross margins hitting an estimated 60%.
There are more acquisitions to close which will ultimately add to these figures as the company continues to establish a solid share of the American legal cannabis market.
Shares slipped $0.16 to $1.43 during trading as the cannabis sector as a whole took a hit on the boards.
Currently C21 Investments has 63,145,780 issued and outstanding shares with a market cap of CAD$90.3 million.
Full disclosure: C21 Investments is an Equity.Guru marketing client.
Disclaimer: ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
Latest posts by Gaalen Engen (see all)
- Pepsi, Nestle and Amazon: asymmetric risk and monopoly control - January 10, 2020
- Icahn’s noxious no-brainers and America’s share buyback binge: Is value extraction a sham? - December 19, 2019
- The U.S. Fed and market liquidity or welcome to the everything bubble - December 13, 2019